ReShape Lifesciences Inc. (RSLS), Thursday announced its decision to reduce its workforce, which is expected to generate annualized savings of over $750,000 or 23.4 percent of annual payroll expenses.
The decision, expected to boost operational efficiency of the company, comes after conducting a thorough review of its operating structure.
Concurrently, the company also shared an update regarding its merger agreement with Vyome Therapeutics and the asset sale to Biorad Medisys. These strategic transactions were unanimously endorsed by the Board of Directors.
In the pre-market hours, RSLS is trading at $2.61, up 6.48 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.